# An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

> **NCT03414983** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 196 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03414983
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2021-02-01
- **Final completion:** 2022-12-28
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03414983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03414983, "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03414983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*